These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
708 related articles for article (PubMed ID: 26183576)
1. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2. Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576 [TBL] [Abstract][Full Text] [Related]
2. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. Mease K; Sane R; Podila L; Taub ME J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351 [TBL] [Abstract][Full Text] [Related]
3. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901 [TBL] [Abstract][Full Text] [Related]
4. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Dahan A; Amidon GL Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926 [TBL] [Abstract][Full Text] [Related]
5. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters. Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889 [TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells. Dai P; Zhu L; Yang X; Zhao M; Shi J; Wang Y; Lu L; Liu Z Life Sci; 2015 Apr; 127():66-72. PubMed ID: 25744397 [TBL] [Abstract][Full Text] [Related]
7. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP. Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967 [TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540 [TBL] [Abstract][Full Text] [Related]
9. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. Choi MK; Song IS J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210 [TBL] [Abstract][Full Text] [Related]
10. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). Shen H; Lee FY; Gan J J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849 [TBL] [Abstract][Full Text] [Related]
11. Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco-2 cell monolayers. Kimura O; Fujii Y; Haraguchi K; Ohta C; Koga N; Kato Y; Endo T J Pharm Pharmacol; 2016 Jul; 68(7):883-9. PubMed ID: 27166429 [TBL] [Abstract][Full Text] [Related]
12. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. Xiao L; Yi T; Chen M; Lam CW; Zhou H Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020 [TBL] [Abstract][Full Text] [Related]
13. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Römermann K; Helmer R; Löscher W Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391 [TBL] [Abstract][Full Text] [Related]
14. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells. Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP. Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Mukkavilli R; Jadhav G; Vangala S Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222 [TBL] [Abstract][Full Text] [Related]
17. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib. Graber-Maier A; Gutmann H; Drewe J Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289 [TBL] [Abstract][Full Text] [Related]
18. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726 [TBL] [Abstract][Full Text] [Related]
19. Characterization of efflux transporters involved in distribution and disposition of apixaban. Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458 [TBL] [Abstract][Full Text] [Related]
20. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Sun S; Chen Z; Li L; Sun D; Tian Y; Pan H; Bi H; Huang M; Zeng S; Jiang H Xenobiotica; 2012 Dec; 42(12):1197-205. PubMed ID: 22900779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]